相关实验视频

Updated: Jun 15, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

在停止抗凝固药物后,左心室血栓复发

Kamran Namjouyan¹, Aastha Mittal¹, Seth Krueger¹

¹Medicine Institute, Geisinger Medical Center, Danville, PA, USA.

International journal of cardiology. Heart & vasculature

|August 26, 2024

概括

左心室血栓 (LVT) 复发发生在前ST段升高心肌梗塞 (STEMI) 患者中10.3%的患者在停止抗凝药后. 心室动脉瘤和多血管疾病增加了复发风险,需要进一步研究最佳抗凝血持续时间.

科学领域:

心脏病学心脏病学
心血管医学心血管医学
血栓形成研究研究

背景情况:

左心室血栓 (LVT) 是前部ST段升高心肌梗塞 (STEMI) 的并发症.
对LVT的最佳抗凝血 (AC) 持续时间尚不清楚.
在STEMI患者中停止AC后,对LVT复发的证据有限.

研究的目的:

评估前期STEMI患者中LVT复发的发生率.
为了确定与LVT复发相关的风险因素.
根据临床决策对抗凝血治疗的持续时间.

主要方法:

追溯分析87名前STEMI患者的LVT和减少射出分数 (<35%).
排除患有心房或高凝血状态的患者.
患者与没有LVT复发之间的人口统计,并发症,治疗和成像特征的比较.

主要成果:

在10.3%的患者中观察到左心室血栓复发.
复发的患者更有可能患上腹腔动脉瘤/痕 (33% vs 10.3%) 和多血管疾病 (22.2% vs 9%).
在9名复发患者中,有3人 (33.3%) 经历了心血管栓塞事件.

结论:

一部分患有LVT的前列STEMI患者在停止抗凝药后面临复发的显著风险.
腹腔动脉瘤和多血管疾病是LVT复发的潜在风险因素.
预期试验对于确定LVT抗凝治疗的适当持续时间至关重要.

关键词:

前部ST升高心肌梗塞心肌梗塞心力衰竭与减少的喷射分数心力衰竭.左心室血栓是左心室的血栓.

更多相关视频

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques

Published on: June 11, 2019

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.